Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets open in the red
Thu, 26 Jun 09:30 am

Barring Malaysia (down 0.3%), the major Asian stock markets have opened in the green with Singapore (up 0.4%) and Hong Kong (up 0.9%) leading the gains.

However, the Indian share markets have opened the day on a negative note. Barring oil and gas, all sectoral indices have opened in the green with stocks in banking and auto sector leading the gains.

The Sensex today is down by around 22 points (0.1%), while the NSE-Nifty is down by around 7 points. The midcap and smallcap stocks have opened in the green with BSE Mid Cap and BSE Small Cap indices up by around 0.3% and 0.4% respectively. The rupee is currently trading at Rs 60.14 to the US dollar.

Auto stocks have opened the day mainly in the green with Force Motors Ltd and Eicher Motors Ltd leading the gains. However, Maruti Suzuki Ltd and Tube Investments Ltd were leading the losses. As per a leading financial daily, Ashok Leyland is planning to raise about Rs 6 to Rs 7 bn through a qualified institutional placement to pare debt. The fund raising is expected to be concluded in the next couple of weeks. As per the sources close to the company, the move may lead to the equity dilution of 6.1% in the company and may bring down promoter's stake to 39% from 41.25% in FY14. It was in August 2013 that the peak debt of the company touched Rs 62 bn. Since then, the company subsequently has been reducing its debt burden gradually through several measures. At the end of FY14, the company's debt stood at Rs 39 bn, with debt to equity ratio standing at 0.87 times, up from 0.78 times in FY13,

Indian Pharma stocks have opened the day on a mixed note with Dishman Pharma Ltd and JB Chemicals Ltd leading the gains. However, Natco Pharma Ltd and Glenmark Pharma Ltd were facing maximum selling pressure. As per a leading financial daily, the domestic Pharma sector is likely to be offered a financing scheme by the Modi government for the upgradation of manufacturing facilities and meet stringent standards of the world's leading export markets. It is important to note here that Indian pharma companies are facing a tough time on account of quality issues raised by US Food and Drug Administation (USFDA). One of the options being considered is an interest subsidy scheme for the upgradation of manufacturing facilities. Besides, the Government is also aims to boost the active ingredients segment of the domestic industry, which has suffered from cheap Chinese imports.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open in the red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.